Chiasma, Inc. (NASDAQ:CHMA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 12, 2016, James R. Tobin resigned from the Board of Directors (the “Board”) of Chiasma, Inc. (the “Company”), including the Audit Committee of the Board (the “Audit Committee”), effective immediately. The decision by Mr. Tobin was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
John A. Scarlett, M.D., an existing member of the Board, was appointed to the Audit Committee to fill the vacancy created by Mr. Tobin’s resignation.
About Chiasma, Inc. (NASDAQ:CHMA)
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication. Chiasma, Inc. (NASDAQ:CHMA) Recent Trading Information
Chiasma, Inc. (NASDAQ:CHMA) closed its last trading session up +0.05 at 1.95 with 187,685 shares trading hands.
